Comparative Pharmacology
Head-to-head clinical analysis: NORMOCARB HF 35 versus THAM E.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NORMOCARB HF 35 versus THAM E.
NORMOCARB HF 35 vs THAM-E
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
NORMOCARB HF 35 is a fixed-dose combination of dapagliflozin (SGLT2 inhibitor) and saxagliptin (DPP-4 inhibitor). Dapagliflozin inhibits sodium-glucose cotransporter 2 in the proximal renal tubule, reducing glucose reabsorption and increasing urinary glucose excretion. Saxagliptin inhibits dipeptidyl peptidase-4, prolonging the action of incretin hormones (GLP-1 and GIP) to enhance insulin secretion and suppress glucagon release in a glucose-dependent manner.
THAM-E (tromethamine) is a sodium-free organic amine that acts as a proton acceptor, buffering excess hydrogen ions in metabolic acidosis. It increases bicarbonate concentration by reducing carbon dioxide tension and enhances renal excretion of hydrogen ions.
Oral: 150 mg twice daily
Intravenous: Initial dose (mL of 0.3 M solution) = body weight (kg) × base deficit (mEq/L) × 1.1. Administer by slow IV infusion, not to exceed 8 mL/kg/hour. Maximum single dose: 48 mL/kg.
None Documented
None Documented
Terminal elimination half-life: 35 hours. In renal impairment (CrCl <30 mL/min), half-life may be prolonged to 90 hours, requiring dose adjustment.
Terminal elimination half-life: 5-10 minutes (2-3 minutes for distribution phase). Clinically negligible accumulation with repeat doses due to rapid renal clearance.
Primarily renal (approx. 90% as unchanged drug), biliary/fecal <10%.
Renal: >95% as unchanged drug; <5% metabolized or excreted in bile/feces.
Category C
Category C
Alkalizing Agent
Alkalizing Agent